Tech Center 1600 • Art Units: 1613 1646 1655
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18126186 | COSMETIC LAMINATE SHEET | Non-Final OA | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. |
| 18517448 | ANTI-TUMOR AGENT | Final Rejection | FUJIFILM Corporation |
| 18572884 | COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES | Non-Final OA | The Regents of the University of Michigan |
| 16468351 | HAIR LIGHTENING COMPOSITION COMPRISING HYDROGEN PEROXIDE, BICARBONATE, AND AT LEAST 0.5% BY WEIGHT OF POLYPHOSPHORUS DERIVATIVE | Non-Final OA | L'OREAL |
| 18642331 | MEDIATION OF IN VIVO ANALYTE SIGNAL DEGRADATION | Non-Final OA | Senseonics, Incorporated |
| 18169695 | HEMOSTATIC NANOPARTICLES FOR THE TREATMENT OF NON-COMPRESSIBLE HEMORRHAGE AND INTERNAL BLEEDING | Non-Final OA | The General Hospital Corporation |
| 18594760 | Oral Care Compositions and Methods of Use | Non-Final OA | Colgate-Palmolive Company |
| 18565098 | AN ANTIPERSPIRANT COMPOSITION | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18722759 | IONIZABLE DISULFIDE LIPIDS AND LIPID NANOPARTICLES DERIVED THEREFROM | Non-Final OA | PROVIDENCE THERAPEUTICS HOLDINGS INC. |
| 17909194 | CANNABIDIOL NANODRUG FORMULATIONS AND METHODS FOR USE OF THE SAME | Final Rejection | UNIVERSITY OF MIAMI |
| 18677400 | COMPOSITION FOR TREATMENT OF WOUNDS CONTAINING STEM CELL-DERIVED EXOSOMES AND METHOD FOR PREPARING SAME | Non-Final OA | BREXOGEN INC. |
| 18709728 | DEVELOPMENT OF A NEW FAMILY OF NANOCARRIERS DERIVED FROM NATURAL TETRAMERIC ACID LIPIDS | Non-Final OA | Norwegian University of Science and Technology |
| 18265563 | Estolide Esters For The Cosmetic Treatment Of Skin | Non-Final OA | CLARIANT INTERNATIONAL LTD |
| 18697259 | Lipid Nanoparticle Compositions for Delivering Circular Polynucleotides | Non-Final OA | Orna Therapeutics, Inc. |
| 18619076 | SOLID PHARMACEUTICAL TABLET | Non-Final OA | Genexa Inc. |
| 18599845 | COMPOSITION FOR THE TREATMENT OF REFRACTORY PAINFUL INTERVERTEBRAL DISC RELATED DISORDERS AND METHOD FOR DELIVERY THEREOF TO TREAT THERETO | Non-Final OA | Progressive Health Partners |
| 18596349 | NOVEL METHODS | Non-Final OA | INTRA-CELLULAR THERAPIES, INC. |
| 18591271 | COATING MATERIAL FOR UNDERWATER STRUCTURES, UNDERWATER STRUCTURE, AND METHOD FOR PRODUCING UNDERWATER STRUCTURE WITH COATING MATERIAL | Non-Final OA | GENERAL INCORPORATED ASSOCIATION MARINE HABITAT IKI |
| 18277346 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | Non-Final OA | MODERNATX, INC. |
| 18294924 | AGENT FOR COMBINATION USE COMPRISING T CELL AND/OR B CELL ACTIVITY REGULATOR | Non-Final OA | TOKAI UNIVERSITY EDUCATIONAL SYSTEM |
| 18015495 | INJECTABLE HIGH-DRUG-LOADED NANOCOMPOSITE GELS AND PROCESS FOR MAKING THE SAME | Non-Final OA | NUECOLOGY BIOMEDICAL INC. |
| 18398765 | METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER | Non-Final OA | Purdue Pharma L.P. |
| 18574036 | PREPARATION METHOD AND CONTAINER FOR A TOPICAL WOUND HEALING GEL | Non-Final OA | REGENLAB USA LLC |
| 18013729 | NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN ACUTE MYELOID LEUKEMIA | Final Rejection | Peter MacCallum Cancer Institute |
| 18568616 | ANTI-SUN COSMETIC COMPOSITION CONTAINING MYCOSPORINE-LIKE AMINO ACIDS | Non-Final OA | Jean-Noël THOREL |
| 18526352 | FORMULATION OF A PAN-JAK INHIBITOR | Non-Final OA | KINASET THERAPEUTICS, INC. |
| 18387442 | SOFT CANDY WITHOUT FISHY TASTE OR ODOR AND PREPARATION METHOD THEREOF | Non-Final OA | JIANGSU YICHAO HEALTH TECHNOLOGY CO., LTD. |
| 18289532 | COMPOSITION FOR PROMOTING NEUROREGENERATION, CONTAINING EXTRACELLULAR VESICLES DERIVED FROM THREE-DIMENSIONAL SPHEROIDAL CELL AGGREGATES | Final Rejection | S&E Bio Co., Ltd. |
| 18555446 | PEPTIDES, NANOVESICLES, AND USES THEREOF FOR DRUG DELIVERY | Non-Final OA | Anjarium Biosciences AG |
| 18375115 | TOPICAL WIPE CONTAINING NIFEDIPINE AND LIDOCAINE | Final Rejection | Steel Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy